Clinical trials: tuberculosis
Tuberculosis
Achieving Tuberculosis (TB) Control In Zambia
To achieve TB control, innovative case finding interventions are needed that will reach the broader affected population including those that do not access the health facilities.
- Trial name
- TB (NCT03497195)
- Testing
- Screening at community level
- Where
- Zambia
- Volunteers
- 18,194 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Tuberculosis, Pulmonary
Azacytidine During Anti-tuberculosis Therapy
Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a…
- Trial name
- AZA (NCT03941496)
- Testing
- Azacitidine Injection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Andrew Dinardo
Tuberculosis
Heterologous Effects of BCG in Healthy UK Adults
TB038 is a clinical study to assess the non-specific effects of BCG vaccination and gain a better understanding of how the body's immune system reacts to BCG and in turn potentially prevents infection from other bacteria.
- Trial name
- NCT02380508
- Testing
- BCG SSI, No vaccination, BCG Sii
- Where
- 3 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, Latent Tuberculosis
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
- Trial name
- LIMBO-TB (NCT06526689)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary TB
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb
Obtain sputum smears within one day to rule out TB
- Trial name
- NCT00212550
- Testing
- Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Tuberculosis
Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose with Food Effect Cohort Trial (Part 1) and Multiple Ascending Dose Trial (Part 2) to Evaluate the Safety, Tolerability, and PK of TBAJ-587…
- Trial name
- NCT04890535
- Testing
- TBAJ-587
- Where
- Netherlands
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Latent Tuberculosis Infection
Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
The overall objective of this study is to assess the feasibility and potential impact of using a targeted testing approach and 2 interferon-gamma release assays (IGRA) to screen for latent tuberculosis (TB) infection (LTBI) among…
- Trial name
- LTBI (NCT00804713)
- Testing
- BST, TST, QFT
- Where
- United States
- Volunteers
- 2,017 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Tuberculosis
Treatment Duration for Abdominal Tuberculosis
Most of the guidelines on the treatment of tuberculosis suggest that 6 months treatment is sufficient for extrapulmonary tuberculosis except for bone tuberculosis and tubercular meningitis.
- Trial name
- RNTCP-DOTS (NCT01124929)
- Testing
- RNTCP Category I treatment for 6 months, RNTCP Category I treatment for 9months
- Where
- India
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Tuberculosis
Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)
The objective is to achieve 90% overall, positive and negative clinical concordance between results of the T-SPOT.TB assay, using cells isolated via density gradient centrifugation and positive selection using the T-Cell Select…
- Trial name
- NCT04141982
- Testing
- T-Cell SelectTM Kit
- Where
- 4 sites in United States, South Africa
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Oxford Immunotec
Tuberculosis, Hiv
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
This is a single-center, open-label, fixed sequence, pharmacokinetic interaction study between bictegravir and tenofovir alafenamide with rifapentine dosed either daily or weekly.
- Trial name
- NCT04551573
- Testing
- Rifapentine daily, Rifapentine weekly
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yale University
Tuberculosis
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route
This is a phase I trial to compare the safety and immunogenicity of candidate TB vaccine MVA85A administered by the aerosol inhaled route and the intradermal route in healthy BCG-vaccinated adult subjects.
- Trial name
- NCT01497769
- Testing
- Aerosol inhaled MVA85A, Intradermal MVA85A
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection
This study will assess the next generation of blood tests for latent TB infection, which may be able to indicate how treatment is working as well as in diagnosis infection.
- Trial name
- NextGen (NCT02512939)
- Testing
- blood test, not yet marketed, no trade name
- Where
- 5 sites in United Kingdom
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- University College, London
Tuberculosis
Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants
Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study of AERAS-404 Tuberculosis (TB) vaccine administered intramuscularly in Bacille Calmette-Guerin (BCG) primed infants.
- Trial name
- C-015-404 (NCT01861730)
- Testing
- AERAS-404
- Where
- 4 sites in South Africa
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Aeras
COVID-19
INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya
Integration of antigen-detecting rapid diagnostic tests (Ag-RDT) for COVID-19 into services that provide care for vulnerable populations such as pregnant women, children, people with HIV infection, and patients with tuberculosis…
- Trial name
- INTEGRATE (NCT05382130)
- Testing
- Test all
- Where
- 2 sites in Cameroon, Kenya
- Volunteers
- 152,082 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Contraception, Tuberculosis
Rifampin and the Contraceptive Implant
It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society.
- Trial name
- NCT04463680
- Testing
- Rifampin 600 MG
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Tuberculosis, Health Care Professionals
Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment
The purpose of this study is to evaluate in hospital environment the knowledge of the health care professionals about fundamental concepts on tuberculosis and the accomplishment to respiratory isolation practices for patients…
- Conditions
- Tuberculosis, Health Care Professionals, Hospital Environment
- Trial name
- NCT00978510
- Where
- Brazil
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Sociedade Cearense de Infectologia
Multidrug-resistant Tuberculosis (MDR-TB)
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures.
- Trial name
- MESTCAR (NCT07017803)
- Where
- 8 sites in Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Tuberculosis, HIV Infections
The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are infected with HIV. In phase I studies, a single vaccination with MVA85A, when administered at a dose of 5 x 10^7pfu intradermally…
- Trial name
- NCT00395720
- Testing
- MVA85A (TB vaccine), MVA 85A
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand
Study Design: Stratified, matched, cluster-randomized, controlled trial Unit of Randomization: Healthcare facility Study Duration: 3 years; prevalence of latent Tuberculosis infection (LTBI) in healthcare workers (HCWs) will be…
- Trial name
- EnTIC (NCT02073240)
- Testing
- Enhanced TB IC Package
- Where
- 22 sites in Thailand, Vietnam
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention